000144835 001__ 144835
000144835 005__ 20240229112639.0
000144835 0247_ $$2doi$$a10.1016/j.radonc.2019.08.006
000144835 0247_ $$2pmid$$apmid:31522880
000144835 0247_ $$2ISSN$$a0167-8140
000144835 0247_ $$2ISSN$$a1879-0887
000144835 0247_ $$2altmetric$$aaltmetric:66562989
000144835 037__ $$aDKFZ-2019-02260
000144835 041__ $$aeng
000144835 082__ $$a610
000144835 1001_ $$0P:(DE-HGF)0$$aGillmann, Clarissa$$b0$$eFirst author
000144835 245__ $$aRBE-weighted doses in target volumes of chordoma and chondrosarcoma patients treated with carbon ion radiotherapy: Comparison of local effect models I and IV.
000144835 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2019
000144835 3367_ $$2DRIVER$$aarticle
000144835 3367_ $$2DataCite$$aOutput Types/Journal article
000144835 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1577972734_11608
000144835 3367_ $$2BibTeX$$aARTICLE
000144835 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144835 3367_ $$00$$2EndNote$$aJournal Article
000144835 500__ $$a2019 Dec;141:234-238
000144835 520__ $$aTo compare the relative biological effectiveness (RBE)-weighted dose distributions in the target volume of chordoma and chondrosarcoma patients when using two different versions of the local effect model (LEM I vs. IV) under identical conditions.The patient collective included 59 patients treated with 20 fractions of carbon ion radiotherapy for chordoma and low-grade chondrosarcoma of the skull base at the Helmholtzzentrum für Schwerionenforschung (GSI) in 2002 and 2003. Prescribed doses to the planning target volume (PTV) were 60 (n = 49), 66 (n = 2) and 70 (n = 8) Gy (RBE). The original treatment plans that were initially biologically optimized with LEM I, were now recalculated using LEM IV based on the absorbed dose distributions. The resulting RBE-weighted dose distributions were quantitatively compared to assess the clinical impact of LEM IV relative to LEM I in the target volume.LEM IV predicts 20-30 Gy (RBE) increased maximum doses as compared to LEM I, while minimum doses are decreased by 2-5 Gy (RBE). Population-based mean and median doses deviated by less than 2 Gy (RBE) between both models.LEM I and LEM IV-based RBE-weighted doses in the target volume may be significantly different. Replacing the applied model in patient treatments may therefore lead to local over- or underdosages in the tumor. If LEM IV is to be tested clinically, comparisons of the RBE-weighted dose distributions of both models are required for the individual patients to assess whether the LEM IV-plan would also be acceptable and prescribed dose as well as clinical outcome data have to be carefully reassessed.
000144835 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000144835 588__ $$aDataset connected to CrossRef, PubMed,
000144835 7001_ $$0P:(DE-He78)440a3f62ea9ea5c63375308976fc4c44$$aJäkel, Oliver$$b1$$udkfz
000144835 7001_ $$0P:(DE-He78)b43076fb0a30230e4323887c0c980046$$aKarger, Christian$$b2$$eLast author$$udkfz
000144835 773__ $$0PERI:(DE-600)1500707-8$$a10.1016/j.radonc.2019.08.006$$gp. S0167814019330452$$p234-238$$tRadiotherapy and oncology$$v141$$x0167-8140$$y2019
000144835 909CO $$ooai:inrepo02.dkfz.de:144835$$pVDB
000144835 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000144835 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)440a3f62ea9ea5c63375308976fc4c44$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000144835 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b43076fb0a30230e4323887c0c980046$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000144835 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000144835 9141_ $$y2019
000144835 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000144835 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIOTHER ONCOL : 2017
000144835 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144835 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144835 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144835 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000144835 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000144835 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144835 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000144835 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144835 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144835 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000144835 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000144835 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000144835 9201_ $$0I:(DE-He78)E040-20160331$$kE040$$lMedizinische Physik in der Strahlentherapie$$x0
000144835 980__ $$ajournal
000144835 980__ $$aVDB
000144835 980__ $$aI:(DE-He78)E040-20160331
000144835 980__ $$aUNRESTRICTED